|Bid||8.53 x 0|
|Ask||8.90 x 0|
|Day's range||8.67 - 8.70|
|52-week range||8.49 - 12.96|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||54.50|
|Forward dividend & yield||0.19 (2.15%)|
|Ex-dividend date||13 May 2022|
|1y target est||N/A|
BARCELONA, Spain, February 20, 2023--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
BARCELONA, Spain, January 04, 2023--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023.
BARCELONA, Spain, November 28, 2022--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem. FACILITATE main